InterAx February 2015, Lausanne, Switzerland: InterAx was two of four companies selected by a jury of successful entrepreneurs and investors to win 10,000 CHF in pre-seed capital. The company will now move on to Stage II of the Venture Kick competition, with an opportunity to win an additional 20,000 CHF.
December 2014, Zürich, Switzerland: InterAx Biotech Co-Founder Martin Ostermaier was selected by a panel of scientific experts as an ETH Zürich Pioneer Fellow. The award was given based on the scientific merit of the arrestin-GPCR complex stabilization technology and its potential in drug screening applications.
